Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and Sintilimab in Second-line Advanced Gastric/GEJ Adenocarcinoma
NCT05625737Phase 2Unknown
- Start
- Sep 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib, sintilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma. Status: unknown.
02
Drugs
fruquintinibsintilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05625737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05625737.